Q1 2013 United States Pharmaceuticals and Healthcare Report
Description:
we caution that further reforms to the healthcare sector are inevitable, due to unsustainable spending on medical services, by both the public and private sectors. – PowerPoint PPT presentation
Despite assertions from some stakeholders, the re-election of Barack Obama as President of the United States is not bad news for pharmaceutical companies and medical device manufacturers,primar ily because we expect continuation of existing policies that have generally been favorable.However, we caution that further reforms to the healthcare sector are inevitable, due to unsustainable spending on medical services, by both the public and private sectors.
Headline Expenditure ProjectionsPharmaceuticals US337.1bn in 2011 to US343.1bn in 2012 1.3 growth in local currency terms. Forecast slightly down from Q412.Healthcare US2,708bn in 2011 to US2,844bn in 2012 5.0 growth in local currency terms. Forecast slightly down from Q412.Medical devices US133bn in 2011 to US138bn in 2012 4.6 growth in local currency terms. Forecast slightly down from Q412.
Inquire for a discount on this report _at_ http//www.rnrmarketresearch.com/contacts/discount ?rname70389
3 RnR Market Research
TABLE OF CONTENTS
Pharmaceutical Market Forecast 42Table Pharmaceutical Sales Indicators 2008-2016 44Key Growth Factors - Industry 45Table Healthcare Expenditure Indicators 2008-2016 47Table Healthcare Governmental Indicators 2008-2016 48Table Healthcare Private Indicators 2008-2016 48Macro Chart Pack - Nominal Growth Picking Up Pace 49Table Macro Indicators 56Prescription Drug Market Forecast 57Table Prescription Drug Sales Indicators 2008-2016 58Table Top 10 Therapeutic Classes By Sales (USbn) 59Table Top 10 Therapeutic Classes By Dispensed Prescriptions (mn) . 59Patented Drug Market Forecast . 60Table Patented Drug Market Indicators 2008-2016 61Generic Drug Market Forecast 62